\-\ Texto\\:\\ \ \(0\)\
\-\ hypertension\ \(298\)\
\-\ blood\\ pressure\\ control\ \(4\)\
\-\ multiple\\ lesions\\ involving\\ both\\ white\\ matter\\ and\\ cortex\\ involving\\ both\\ cerebral\\ hemispheres\\ and\\ cerebellum\\.\ \(0\)\
\-\ no\\ mass\\ effect\\ nor\\ enhancement\\ nor\\ restricted\\ diffusion\\.\ \(0\)\
\-\ posterior\\ reversible\\ encephalopathy\\ syndrome\\ \\(pres\\)\ \(0\)\
\-\ \\â\\€\\¢\\ cerebral\\ infarction\ \(1\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ \\â\\€\\¢\\ pres\ \(0\)\
\-\ 33\\ year\\ old\\ man\\ with\\ end\\ stage\\ renal\\ disease\\.\ \(1\)\
\-\ recent\\ decreased\\ level\\ of\\ consciousness\\.\ \(0\)\
\-\ pres\\ should\\ be\\ reversible\\ after\\ removing\\ the\\ inciting\\ factor\\ and\\ controlling\\ hypertension\\ \\(if\\ present\\)\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pres\\:\\ 0\\.49720638931912675\ \(0\)\
\-\ reversible\\:\\ 0\\.310467155260928\ \(0\)\
\-\ nor\\:\\ 0\\.2613422285012075\ \(0\)\
\-\ hypertension\\:\\ 0\\.2054140800000516\ \(0\)\
\-\ removing\\:\\ 0\\.18881602363767408\ \(0\)\
\-\ involving\\:\\ 0\\.1880456066208954\ \(0\)\
\-\ cerebral\\:\\ 0\\.1859960798406944\ \(0\)\
\-\ controlling\\:\\ 0\\.17679543830738692\ \(0\)\
\-\ inciting\\:\\ 0\\.1706215662815501\ \(0\)\
\-\ both\\:\\ 0\\.149710125923932\ \(0\)\
\-\ encephalopathy\\:\\ 0\\.1414019696751482\ \(0\)\
\-\ hemispheres\\:\\ 0\\.13034199447413689\ \(0\)\
\-\ factor\\:\\ 0\\.12588881221605347\ \(0\)\
\-\ consciousness\\:\\ 0\\.1253539782751251\ \(0\)\
\-\ cerebellum\\:\\ 0\\.12332849808899451\ \(0\)\
\-\ 33\\:\\ 0\\.11812612436812168\ \(0\)\
\-\ end\\:\\ 0\\.11812612436812168\ \(0\)\
\-\ restricted\\:\\ 0\\.11537611006313096\ \(0\)\
\-\ control\\:\\ 0\\.1146939846091827\ \(0\)\
\-\ diffusion\\:\\ 0\\.11307046640589391\ \(0\)\
\-\ disease\\:\\ 0\\.11269271379553927\ \(0\)\
\-\ cortex\\:\\ 0\\.10930895785931434\ \(0\)\
\-\ stage\\:\\ 0\\.10689659438005707\ \(0\)\
\-\ infarction\\:\\ 0\\.10537789452568151\ \(0\)\
\-\ pressure\\:\\ 0\\.10220741018182816\ \(0\)\
\-\ matter\\:\\ 0\\.10220741018182816\ \(0\)\
\-\ effect\\:\\ 0\\.09416287325034171\ \(0\)\
\-\ recent\\:\\ 0\\.09088931524005577\ \(0\)\
\-\ white\\:\\ 0\\.08856330664825222\ \(0\)\
\-\ should\\:\\ 0\\.0875871983989299\ \(0\)\
\-\ renal\\:\\ 0\\.08359084858562399\ \(0\)\
\-\ and\\:\\ 0\\.08321298376625519\ \(0\)\
\-\ decreased\\:\\ 0\\.08314684144290885\ \(0\)\
\-\ level\\:\\ 0\\.08108466060884728\ \(0\)\
\-\ syndrome\\:\\ 0\\.08092403418023278\ \(0\)\
\-\ lymphoma\\:\\ 0\\.07994422235228003\ \(0\)\
\-\ if\\:\\ 0\\.07799286399842116\ \(0\)\
\-\ blood\\:\\ 0\\.07795755764457676\ \(0\)\
\-\ enhancement\\:\\ 0\\.0772623318821516\ \(0\)\
\-\ lesions\\:\\ 0\\.07709168805659852\ \(0\)\
\-\ metastatic\\:\\ 0\\.07362023214874087\ \(0\)\
\-\ man\\:\\ 0\\.07106475831284093\ \(0\)\
\-\ posterior\\:\\ 0\\.0694131802696819\ \(0\)\
\-\ present\\:\\ 0\\.06887944917379811\ \(0\)\
\-\ multiple\\:\\ 0\\.06565641244336806\ \(0\)\
\-\ after\\:\\ 0\\.06511875839512615\ \(0\)\
\-\ be\\:\\ 0\\.05445307014995652\ \(0\)\
\-\ mass\\:\\ 0\\.05127352468353915\ \(0\)\
\-\ no\\:\\ 0\\.043651131090363185\ \(0\)\
\-\ year\\:\\ 0\\.04136805012442969\ \(0\)\
\-\ old\\:\\ 0\\.039727648025374096\ \(0\)\
\-\ the\\:\\ 0\\.026784400704834968\ \(0\)\
\-\ with\\:\\ 0\\.02628455188205266\ \(0\)\
\-\ of\\:\\ 0\\.026268856246704775\ \(0\)\
